Premedication after grade 1 infusion reaction

Vantrexa · Metastatic NSCLC

MI-2026-0663UrgentClosedBreachedSafety

RARachel AdeyemiMSL, Oncology (UK & Ireland)

Restricted — potential adverse event

Access limited to Medical Information and Safety roles. Details are captured minimally and routed to pharmacovigilance per SOP-PV-014. AI features are disabled for this record (PRD §27.7).

Received: 20 Aug 2026, 18:04 UTC
Channel: Congress booth
Requestor type: Internal
Country / region / team: Germany · Europe · MI Europe
Category: Safety
Response type: Custom response
Owner: RARachel Adeyemi
Due: 22 Aug 2026, 18:04 UTC
Responded: 24 Aug 2026, 19:04 UTC
Quality review: Passed
Related insight: —
Related standard response: None matched (topic-keyword match)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Received
Triage
Assigned
In progress
Escalated
Draft response
Medical review
Quality review
Sent
Follow-up required
11Closed
12Archived

Current stageClosedDemo action — not persisted

SLA

Urgent: 48 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

Elapsed

97 h

to response

Breached by

49 h

100%

Timeline

20 Aug 2026, 18:04 UTC
Received via Congress booth
Internal · Germany
20 Aug 2026, 18:04 UTC
Triage and assignment
Urgency Urgent · assigned to MI Europe
22 Aug 2026, 18:04 UTC
SLA due (48 h)
24 Aug 2026, 19:04 UTC
Response sent
Custom response · quality review passed

Draft response

Restricted record

AI suggestion disabled — safety-flagged inquiries are not interpreted by AI (PRD §27.7).

Draft response

Audit history

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 20 Aug 2026 · hourly sync.